<prompt> Answer this question truthfullyWhat is the recommended medical treatment for leiomyosarcoma?  <response>: <reason> Chemotherapy is recommended for individuals who have locally advanced, metastatic, or recurrent disease. Usually in combination with surgical procedures andor radiation. The treatment is to use drugs to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Anthracyclines stops the tumor growth by different mechanism such as intercalating into deoxyribonucleic acid DNA, blocking DNA and ribonucleic acid RNA synthesis, also causing DNA breakage by interfering with topoisomerase II activity. Most common drugs used as first line treatment of soft tissue sarcoma include combination of ifosfamide and doxorubicin Adriamycin. Surgical resection of localized disease is a mainstay therapeutic strategy. In the event tumors have metastasized or spread beyond uterus and not resectable by surgery, cytotoxic chemotherapeutic agents can be used in combination with radiation therapy. Some of these chemotherapeutic agents are gemcitabine, docetaxel, ifosfamide, temozolomide, trabectedin, eribulin.Regimen includes the following: Doxorubicin 60 mgm2 every 3 wk; doses as high as 75 mgm2 can be given; however, this can be administered as a split dose over 3 d 25 mgm2day for 3 d; maximum lifetime dose is 475-600 mgm2 orLiposomal pegylated doxorubicin: doses as high as 50 mgm2 every 4 wk have been used in clinical trials; however, this is associated with significant toxicity; commonly used doses include 30-35 mgm2 every 4 wk; no maximum lifetime doses orIfosfamide 2000-3000 mgm2day IV over 3 h for 3-4 d plus mesna; repeat every 21 d orIfosfamide 5000 mgm2 over 24 h plus mesna 5000 mgm2 over 24 h and an additional 400-600 mgm2 for 2 h after completion of ifosfamide; repeat every 21 d European schedule orGemcitabine 1200 mgm2 IV over 90-120min on days 1 and 8; repeat cycle every 21d orTrabectedin 1.5 mgm2 IV q3wk until disease progression or unacceptable toxicity; premedication require and infuse via central line over 24h Epirubicin 160 mgm2 IV bolus every 3 wk with growth factor support orDacarbazine 250 mgm2 IV for 5 d or 800-1000 mgm2 IV every 3 wk orPazopanib 800 mg PO qd not indicated for liposarcoma outside of a clinical trial; FDA approved as second-line chemotherapy; recommend starting at a low dose of 200 mg for 2 weeks and slowly increasing the dose 